Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (101-110 of 339) with videos related to

Pageof 34
Sort By:
Journal of Clinical Medicine|October 28, 2023
Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms-Real-World Data from the German Noninterventional Study EXCALIBURFelicitas Schulz, Ulrich Hauch, Sandra Ketzler-Henkel, et al.
Leukemia Research|March 22, 2017
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.
Haematologica|January 28, 2014
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring systemEsther Zipperer, Nina Tanha, Corinna Strupp, et al.
Leukemia Research|November 6, 2012
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blastsAnna Maassen, Corinna Strupp, Aristoteles Giagounidis, et al.
European Journal of Haematology|May 14, 2021
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDSChristina Rautenberg, Michael Lauseker, Jennifer Kaivers, et al.
Leukemia Research|May 2, 2015
Change of prognosis of patients with myelodysplastic syndromes during the last 30 yearsJudith Neukirchen, Kathrin Nachtkamp, Jennifer Schemenau, et al.
Haematologica|December 6, 2006
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromesUlrich Germing, Corinna Strupp, Andrea Kuendgen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 19, 2019
Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous LeukemiaThomas Schroeder, Nadija Wegener, Michael Lauseker, et al.
Annals of Hematology|January 10, 2025
Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experienceFelicitas Schulz, Claudia Roggenbuck, Andrea Kündgen, et al.
Annals of Hematology|March 31, 2016
Causes of death in 2877 patients with myelodysplastic syndromesKathrin Nachtkamp, Romina Stark, Corinna Strupp, et al.
Pageof 34

Showing results (101-110 of 339) with videos related to

Sort By:
Pageof 34
Journal of Clinical Medicine|October 28, 2023
Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms-Real-World Data from the German Noninterventional Study EXCALIBURFelicitas Schulz, Ulrich Hauch, Sandra Ketzler-Henkel, et al.
Leukemia Research|March 22, 2017
New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS typesCorinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, et al.
Haematologica|January 28, 2014
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring systemEsther Zipperer, Nina Tanha, Corinna Strupp, et al.
Leukemia Research|November 6, 2012
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blastsAnna Maassen, Corinna Strupp, Aristoteles Giagounidis, et al.
European Journal of Haematology|May 14, 2021
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDSChristina Rautenberg, Michael Lauseker, Jennifer Kaivers, et al.
Leukemia Research|May 2, 2015
Change of prognosis of patients with myelodysplastic syndromes during the last 30 yearsJudith Neukirchen, Kathrin Nachtkamp, Jennifer Schemenau, et al.
Haematologica|December 6, 2006
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromesUlrich Germing, Corinna Strupp, Andrea Kuendgen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 19, 2019
Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous LeukemiaThomas Schroeder, Nadija Wegener, Michael Lauseker, et al.
Annals of Hematology|January 10, 2025
Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experienceFelicitas Schulz, Claudia Roggenbuck, Andrea Kündgen, et al.
Annals of Hematology|March 31, 2016
Causes of death in 2877 patients with myelodysplastic syndromesKathrin Nachtkamp, Romina Stark, Corinna Strupp, et al.
Pageof 34